
Shares of drugmaker AbbVie ABBV.N fall 3.5% at $220 in early trading
ABBV's sales from its aesthetics products portfolio, which includes anti-wrinkle treatment Botox, fell 3.7% from last year
"Another weaker quarter for the Aesthetics business could raise some eyebrows... continued headwinds mount across products, including Botox and fillers," says BMO Capital Markets analyst Evan Seigerman
Co reports Q3 adj. profit of $1.86/shr vs analysts' average estimate of $1.77/shr - LSEG data
Co's quarterly revenue of $15.78 billion beats analysts' average expectation of $15.59 billion
ABBV raises annual profit forecast to $10.61-$10.65/shr from its previous forecast of $10.38-$10.58/shr
Including sessions move, stock up ~28% YTD